This was a regulatory safety program of canagliflozin, the first FDA-approved SGLT-2 inhibitor, in patients with type 2 DM and cardiovascular disease or at high risk of cardiovascular disease [76,134]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.